LivaNova, a medical technology company, has received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S. Food and Drug Administration (FDA) for LifeSPARC, the company’s next-generation Advanced Circulatory Support (ACS) pump and controller system.
Castleski Shutterstock
422429341
Rubber stamping that says 'FDA Approved'.
LivaNova leveraged existing real-world evidence inclusive of data collected during the COVID-19 pandemic to receive this new indication.
Dr. Raymond Yau, director of cardiogenic shock at Heart Hospital of New Mexico in Albuquerque, said: “The onset of the global pandemic elevated ECMO to the forefront as an effective treatment option for patients in need of emergent rescue who had limited, if any, options. The past couple of years have demonstrated the inherent value of the LifeSPARC system, which offers even the sickest patients a chance at survival. With LifeSPARC, simplified and streamlined ECMO is in reach for healthcare centres of all sizes.”
The LifeSPARC pump and controller system simplifies ECMO to ensure that hospitals of all sizes can access this high level of life support. The LifeSPARC controller was designed to remove complexity often seen with ECMO devices, instead offering a streamlined user interface and simple navigation panel. This simplicity increases accessibility and ease of use for hospital staff. The LifeSPARC pump is centrifugal and designed to reduce priming time to minutes. The on-patient pump design allows for a miniaturised circuit, making it easy to transport within the hospital and optimising circuit management for intensive care unit staff. This led to swift device adoption by customers, providing ECMO to critically ill patients during the COVID-19 pandemic.
LifeSPARC received an initial 510(k) FDA clearance in July 2019 for up to six hours of use for cardiopulmonary bypass. In April 2020 and with the onset of the COVID-19 pandemic, the FDA issued temporary emergency guidelines for ECMO therapy beyond six hours. Several products within the LivaNova ACS portfolio, including LifeSPARC, were included in the temporary guidance and thereby made available to support COVID-19 patients across the U.S. This latest 510(k) clearance allows for the LifeSPARC system to be used for ECMO beyond six hours with patients in acute respiratory failure or acute cardiopulmonary failure, including but not limited to those receiving treatment for COVID-19.
Ryan Miller, president of the ACS business unit at LivaNova, said: “There is a growing need for simplified life support and with the LifeSPARC pump and controller, we have the opportunity to make ECMO an option for more patients in more places. Since FDA published an enforcement policy to temporarily expand indications in 2020, many hospitals began using LifeSPARC and experienced its benefits first-hand. With the relative simplicity and portability of the system, more patients can have access to life-saving ECMO regardless of the hospital size where they are treated.”
The LifeSPARC System was built on more than 20 years of life support experience with TandemHeart, the first-generation ACS system. LifeSPARC simplified the priming process and increased the power of the pump, while leveraging the strengths of the previous generation system. The console and pump are complemented by four ready-to-deploy kits that offer cannulation configurations to support cardiac and cardiopulmonary conditions. LifeSPARC assists in circulating a patient’s blood when part of an extracorporeal circuit, including physiologic gas exchange. It is intended for use in adult patients with acute respiratory failure or acute cardiopulmonary failure, where other available treatment options have failed, and continued clinical deterioration is expected or the risk of death is imminent.
